{
    "clinical_study": {
        "@rank": "124318", 
        "acronym": "FOLOTOX", 
        "arm_group": [
            {
                "arm_group_label": "Botox Injection", 
                "arm_group_type": "Experimental", 
                "description": "Patients treated by botulinum toxin."
            }, 
            {
                "arm_group_label": "Saline Solution", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients treated with saline solution."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this randomized controlled study is to quantify the modification during\n      locomotion of chronic hemiparetic patients of the strength and the length of Rectus Femoris\n      and Triceps Surae induced by botulinum toxin injection type A.\n\n      The main hypotheses of this study based on previous studies are that botulinum toxin\n      injection increases on one hand the length of the muscle injected during gait and on the\n      other hand decreased the strength of the muscles injected.\n\n      The investigators also hypothesized that botulinum toxin injection improved the strength of\n      the antagonist muscles and normalized the pattern of strength of the muscles injected during\n      gait."
        }, 
        "brief_title": "Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO", 
        "detailed_description": {
            "textblock": "The aim of this study is to compare versus placebo the effects of BTX-A injection on :\n\n        -  the maximal length of the muscles injected during gait\n\n        -  the maximal lengthening velocity of the muscles injected during gait\n\n        -  the maximal strength of muscles injected during gait\n\n        -  the inter-limb coordination assessed by continuous relative phase\n\n        -  the kinematic parameters such as peak knee flexion during swing phase of the gait cycle\n           and peak ankle dorsiflexion during stance phase.\n\n      To that end each patient included in the study will be assessed before injection, one month\n      after the BTX-A injection and 3 months after BTX-A injections.\n\n      All patients will underwent a clinical examination, a 3D gait analysis and a isokinetic\n      dynamometer analysis.\n\n      The comparison of the results in the group treated by BTX-A will permit to show that one\n      month after BTX-A injection peak length during gait of muscles injected, maximal lengthening\n      velocity  peak knee flexion during swing phase and peak ankle dorsiflexion increase\n      significantly.\n\n      It will also permit to show that the maximal strength of muscles injected decreases whereas\n      the strength of antagonist increases It will also permit to demonstrate that multisite BTX-A\n      injection improve coordination of paretic and non paretic lower limb the inter-group\n      comparison will permit to demonstrate that these modification are mainly due to multisite\n      BTX-A injections."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  men or women aged > 18 ans\n\n          -  unilateral stroke more than 6 months\n\n          -  ability to walk 10 meters without assistive device\n\n          -  decrease of peak knee flexion in swing phase of the gait cycle due to a spasticity of\n             Rectus femoris muscle\n\n          -  plantarflexion in swing phase of the gait cycle  due to a spasticity of the triceps\n             surae\n\n          -  informed consent approved\n\n          -  oral contraception\n\n        Exclusion Criteria:\n\n          -  Aphasia\n\n          -  anteriority of lower limb surgery\n\n          -  underlying disease\n\n          -  pre-existing neuro-muscular disorders\n\n          -  pregnancy\n\n          -  absence of oral contraception\n\n          -  last botulinum toxin injection  < 3months\n\n          -  hypersensitivity reactions\n\n          -  co-administration of aminoglycosides"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01821573", 
            "org_study_id": "P110136 / AOM11223", 
            "secondary_id": "2012-001203-21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Botox Injection", 
                "description": "Experimental arm group:\n150 Units in rectus femoris ( 3 ml and 3 points)\n70 units in medial gastrocnemius  (1.4 ml and 1 point)\n70 units in lateral  gastrocnemius  ( 1.4 ml and 1 point)\n60 units in soleus ( 1.2 ml and 3 points)", 
                "intervention_name": "botulinum toxin type A", 
                "intervention_type": "Drug", 
                "other_name": "Botox\u00ae allergan Inc"
            }, 
            {
                "arm_group_label": "Saline Solution", 
                "description": "Placebo comparator group: injection of NaCl 0.9%:\n3 ml of NaCl 0.9% in rectus femoris in 3 points\n1.4 ml of NaCl 0.9% in medial gastrocnemius in  1 point\n1.4 ml of Nacl 0.9% in lateral gastrocnemius  in 1 point\n1.2 ml of NaCl 0.9% in  soleus  in 3 points", 
                "intervention_name": "injection of NaCl 0.9%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Botulinum Toxins, Type A", 
                "Botulinum Toxins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "botulinum toxin injection,3D motion analysis, muscular lengthening,muscle strength", 
        "lastchanged_date": "January 21, 2014", 
        "location": [
            {
                "contact": {
                    "email": "olivier.remyneris@chu-brest.fr", 
                    "last_name": "Olivier Remy-Neris, MD", 
                    "phone": "+33 (0)2 98 22 36 34"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France", 
                        "state": "Bretagne", 
                        "zip": "29290"
                    }, 
                    "name": "Service de m\u00e9decine physique et r\u00e9adaptation CHU de Brest"
                }, 
                "investigator": {
                    "last_name": "Olivier Remy-Neris, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "roche.nicolas@rpc.aphp.fr", 
                    "last_name": "Nicolas Roche, MD", 
                    "phone": "+33 (0)1 47 10 79 00", 
                    "phone_ext": "54 09"
                }, 
                "facility": {
                    "address": {
                        "city": "Garches", 
                        "country": "France", 
                        "state": "Hauts-de-Seine", 
                        "zip": "92380"
                    }, 
                    "name": "Nicolas Roche"
                }, 
                "investigator": [
                    {
                        "last_name": "Djamel Bensmail, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Nicolas ROCHE, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "carne.pierre@ladapt.net", 
                    "last_name": "Pierre Carn\u00e9, MD", 
                    "phone": "+33 (0)2 38 28 17 17"
                }, 
                "facility": {
                    "address": {
                        "city": "Amilly", 
                        "country": "France", 
                        "state": "Loiret", 
                        "zip": "45420"
                    }, 
                    "name": "Centre de r\u00e9\u00e9ducation de l'ADAPT Montargis"
                }, 
                "investigator": {
                    "last_name": "Pierre Carn\u00e9, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double Blind Randomized Controlled Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength of These Muscles During Locomotion in Chronic Hemiparetic Patients", 
        "overall_contact": {
            "email": "roche.nicolas@rpc.aphp.fr", 
            "last_name": "Nicolas Roche, MD", 
            "phone": "00 33 1 47 10 79 00", 
            "phone_ext": "54 09"
        }, 
        "overall_official": {
            "affiliation": "Physical medicine and rehabilation Department, H\u00f4pital RAYMOND POINCARE, 92380 Garches, France", 
            "last_name": "Nicolas Roche, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: Mistry of health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The maximal length of the muscles treated by Botulinum Toxin during locomotion quantified using 3D motion analysis and musculo-skeletal model.\nThis measure will be performed one month after Botulinum toxin injection.", 
            "measure": "Measure of the maximal length of the muscles treated by Botulinum", 
            "safety_issue": "Yes", 
            "time_frame": "1.5 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01821573"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The maximal strength developed by injected muscles during gait.", 
                "measure": "The maximal strength measure", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 hours"
            }, 
            {
                "description": "The modification of inter-segmental coordination during locomotion  induced by botulinum toxin and quantified by continuous relative phase injection", 
                "measure": "Inter-segmental coordination measure", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 hours"
            }, 
            {
                "description": "The modification of joint torque at knee and ankle level induced by botulinum toxin injection.", 
                "measure": "Measure of joint torque at knee and ankle level.", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 hours"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}